DA Davidson set a $21.00 target price on Joint (NASDAQ:JYNT) in a research note released on Thursday, TipRanks reports. The brokerage currently has a buy rating on the stock.

Several other equities analysts also recently issued reports on the stock. Zacks Investment Research raised shares of Joint from a hold rating to a strong-buy rating and set a $22.00 price target for the company in a report on Tuesday, May 14th. TheStreet raised shares of Joint from a d rating to a b rating in a report on Friday, April 26th. Lake Street Capital lifted their price target on shares of Joint to $20.00 and gave the company a buy rating in a report on Friday, March 8th. Maxim Group reissued a buy rating and set a $18.00 price target (up from $11.00) on shares of Joint in a report on Friday, March 8th. Finally, ValuEngine raised shares of Joint from a buy rating to a strong-buy rating in a report on Wednesday, February 20th. Four research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. The company presently has a consensus rating of Buy and an average target price of $18.60.

Shares of JYNT stock opened at $16.44 on Thursday. Joint has a 12-month low of $6.51 and a 12-month high of $19.81. The stock has a market cap of $226.63 million, a P/E ratio of 411.00, a PEG ratio of 7.76 and a beta of 0.86. The company has a quick ratio of 1.00, a current ratio of 1.00 and a debt-to-equity ratio of 4.38.

Joint (NASDAQ:JYNT) last announced its quarterly earnings results on Thursday, May 9th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.06. Joint had a net margin of 4.50% and a return on equity of 109.02%. The firm had revenue of $10.68 million during the quarter, compared to the consensus estimate of $8.90 million. On average, equities research analysts expect that Joint will post 0.22 EPS for the current fiscal year.

In other Joint news, Director Ronald V. Davella sold 10,190 shares of the firm’s stock in a transaction dated Friday, May 24th. The shares were sold at an average price of $16.46, for a total value of $167,727.40. Following the completion of the sale, the director now owns 15,457 shares in the company, valued at approximately $254,422.22. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 6.10% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of JYNT. Marshall Wace North America L.P. acquired a new stake in Joint in the 1st quarter valued at about $47,000. JPMorgan Chase & Co. acquired a new stake in Joint in the 1st quarter valued at about $66,000. SEI Investments Co acquired a new stake in Joint in the 1st quarter valued at about $67,000. Citigroup Inc. acquired a new stake in Joint in the 1st quarter valued at about $133,000. Finally, Northern Trust Corp increased its position in Joint by 16.1% in the 4th quarter. Northern Trust Corp now owns 16,614 shares of the company’s stock valued at $138,000 after acquiring an additional 2,300 shares in the last quarter. Hedge funds and other institutional investors own 47.76% of the company’s stock.

About Joint

The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics. The company operates through two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and the sale of regional developer rights. As of March 07, 2019, the company operated 450 clinics in the United States.

Recommended Story: Net Asset Value

Receive News & Ratings for Joint Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Joint and related companies with MarketBeat.com's FREE daily email newsletter.